Enterprise Value

124B

Cash

5.86B

Avg Qtr Burn

N/A

Short % of Float

0.27%

Insider Ownership

0.01%

Institutional Own.

16.80%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Andexxa (andexanet alfa) Details
Intracranial haemorrhage

Phase 4

Update

Approved

Update

Approved

Update

Calquence (acalabrutinib) Details
Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma

Approved

Update

Beyfortus (Nirsevimab) Details
Respiratory syncytial virus, Viral infection, Respiratory virus

Approved

Quarterly sales

Ultomiris Details
Rare diseases, MYASTHENIA GRAVIS, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome

Approved

Quarterly sales

Lynparza w/ abiraterone and prednisone or prednisolone Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

Soliris (eculizumab) Details
MYASTHENIA GRAVIS, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome

Approved

Quarterly sales

Approved

Quarterly sales

Tagrisso + chemotherapy Details
Lung cancer, Cancer, EGFR-mutated advanced lung cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Dato-DXd (Datopotamab deruxtecan) Details
Lung cancer, Non-small cell lung carcinoma, Cancer

PDUFA

Approval decision

Enhertu Details
Solid tumor/s, Cancer

PDUFA

Approval decision

PDUFA

Approval decision

Ultomiris Details
Rare diseases, Autoimmune disease, Neuromyelitis optica spectrum disorder (NMOSD)

sNDA

FDA meeting

NDA

Submission

Tozorakimab Details
Acute respiratory distress syndrome, Respiratory conditions, Lung disease

Phase 3

Data readout

Saphnelo Details
Idiopathic pulmonary fibrosis

Phase 3

Data readout

Tagrisso Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Phase 3

Data readout

LYNPARZA Details
Solid tumor/s, Cancer, Ovarian cancer

Phase 3

Data readout

Orpathys + Tagrisso Details
Cancer, Solid tumor/s

Phase 3

Data readout

Fasenra Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Phase 3

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 3

Data readout

Dato-DXd Details
Cancer, Breast cancer

Phase 3

Data readout

Imfinzi (mono/combo) Details
Cancer, Liver cancer

Phase 3

Data readout

Tezspire (tezepelumab) Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

LYNPARZA Details
Cancer, Solid tumor/s, Ovarian cancer

Phase 3

Data readout

Tagrisso Details
Lung cancer, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Imfinzi (durvalumab) Details
Lung cancer, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Koselugo (selumetinib, MEK inhibitor) Details
Cancer, Solid tumor/s, Neurofibromatosis type 1

Phase 3

Data readout

Imfinzi Details
Cancer, Bladder cancer

Phase 3

Data readout

Fasenra Details
Coronary Microvascular Dysfunction

Phase 3

Data readout

Enhertu Details
Cancer, Breast cancer

Phase 3

Data readout

Capivasertib Details
Breast cancer, Cancer, Triple-negative breast cancer

Phase 3

Data readout

Imfinzi (durvalumab) Details
Lung cancer, Cancer, Small cell lung cancer

Phase 3

Data readout

Phase 3

Data readout

Voydeya (Danicopan) Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Update

Fasenra Details
Coronary Microvascular Dysfunction

Phase 3

Update

Imfinzi comb w/ neoadjuvant chemotherapy Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Update

roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

Imfinzi comb w/ chemotherapy Details
Cancer, Gastroesophageal junction tumors, Gastric cancer

Phase 3

Update

Phase 3

Update

Imfinzi (durvalumab) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Update

Imfinzi + Lynparza Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 3

Update

Farxiga Details
Acute myocardial infarction

Phase 3

Update

Phase 2b

Data readout

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Data readout

Phase 2

Data readout

Baxdrostat Details
Pulmonary hypertension

Phase 2

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 2

Data readout

Enhertu Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer

Phase 1/2

Data readout

LB-001 Details
Methylmalonic acidemia, Genetic disorder, Rare genetic disease

Phase 1/2

Interim update

ECC5004 Details
Obesity, Type 2 diabetes

Phase 1

Data readout

Phase 1

Data readout

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 1

Data readout